| 16.52 0.14 (0.85%) | 10-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.05  |
1-year : | 24.59 |
| Resists | First : | 18.03 |
Second : | 21.05 |
| Pivot price | 16.29  |
|||
| Supports | First : | 16.05 |
Second : | 14.82 |
| MAs | MA(5) : | 16.33 |
MA(20) : | 16.23 |
| MA(100) : | 17.96 |
MA(250) : | 19.09 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 56.4 |
D(3) : | 56.3 |
| RSI | RSI(14): 46.1 |
|||
| 52-week | High : | 29.64 | Low : | 12.26 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TNDM ] has closed below upper band by 29.2%. Bollinger Bands are 76.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 16.89 - 16.96 | 16.96 - 17.02 |
| Low: | 16.2 - 16.28 | 16.28 - 16.35 |
| Close: | 16.4 - 16.52 | 16.52 - 16.63 |
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
Tue, 20 Oct 2026
Tandem Diabetes Care, Inc. (TNDM) Stock forecasts - Yahoo Finance UK
Tue, 20 Oct 2026
Form 4 Tandem Diabetes Care Inc: Jean-Claude Kyrillos (EVP & Chief Operating Officer) For: 15 October - Investing.com Nigeria
Mon, 19 Oct 2026
After a COO stock conversion, Tandem Diabetes Care (TNDM) withheld 1,926 shares for taxes; none were sold. - Stock Titan
Fri, 16 Oct 2026
Why Did TNDM Stock Jump 5% After Hours Despite Q4 Earnings Miss? - Stocktwits
Tue, 13 Oct 2026
Tandem Diabetes Care (NasdaqGM:TNDM) Stock Forecast & Analyst Predictions - Simply Wall Street
Thu, 01 Oct 2026
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026 - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 70 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 115.8 (%) |
| Shares Short | 13,370 (K) |
| Shares Short P.Month | 11,750 (K) |
| EPS | -0.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.87 |
| Profit Margin | -6.1 % |
| Operating Margin | -5.5 % |
| Return on Assets (ttm) | -2.7 % |
| Return on Equity (ttm) | -48.1 % |
| Qtrly Rev. Growth | 5.8 % |
| Gross Profit (p.s.) | 8.38 |
| Sales Per Share | 14.94 |
| EBITDA (p.s.) | -0.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -44 (M) |
| PE Ratio | -18.16 |
| PEG Ratio | 0 |
| Price to Book value | 8.78 |
| Price to Sales | 1.1 |
| Price to Cash Flow | -208.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|